The faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center have developed guidelines on how to best utilize certain treatments recently approved by the Food and Drug Administration (FDA). The guidelines were drafted using data from available clinical trials and presented for feedback and expert consensus to a diverse group which includes physicians, nurses, clinical investigators, lab investigators, translational researchers, administrators, and patient advocates. We are pleased to share our recommended guidelines which may be a helpful reference when using these new agents. In our discussions, we considered:
The reports include reviews of the clinical trials that led to FDA approval as well as the above-mentioned recommendations for patient selection and treatment.
Treatment Guidelines: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on October 15 and November 5, 2021, to discuss recommendations for the use of abemaciclib in patients with early-stage, high-risk, HR+ breast cancer.Treatment Guidelines: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on August 4, September 3, and October 8, 2021 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.
